The Munich-based start-up Meliodays Medical has successfully closed an oversubscribed pre-seed financing round, raising over EUR 800,000 to advance the development of its novel, hormone-free therapy for the local treatment of menstrual pain.
Meliodays Medical GmbH, a pharma start-up from Munich specializing in women’s health, announced the successful completion of its pre-seed financing round, totaling over EUR 800,000. The round was led by capacura GmbH, with participation from FS Life Science Investment GmbH, along with additional early-stage investors and business angels focused on the healthcare sector.
Approximately 80% of menstruating individuals experience period pain, and for about 20 to 30%, the symptoms are severe enough to interfere with school, work, or social activities. Existing treatment options, including hormonal therapies and high-dose painkillers, often come with systemic side effects.
Meliodays Medical is developing MelioOne, a novel, hormone-free therapy designed to act locally and provide targeted relief from menstrual pain. Based on a proven polymer technology, a small dose of pain medication is released directly into the uterus, aiming to minimize side effects and significantly improve patients’ quality of life.
The funds raised will be used to complete preclinical development and prepare for subsequent regulatory steps. In the long term, the company plans to expand its technology to address other indications such as endometriosis.
Meliodays Medical has already secured patent rights for MelioOne in over 150 countries to support the international scaling of its therapy.